Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics Inc (NQ: CGTX )

0.4398 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after gaining 8% on Thursday. NKGen Biotech presented Phase I clinical trial data at the 16th Annual... 
Via Benzinga
Cognition Therapeutics's Earnings Outlook
Via Benzinga
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Endeavor Group Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Gainers Appreciate Holdings, Inc. (NASDAQ: SFR) shares surged 103.8% to $0.2460 in pre-market trading after falling around 19% on Wednesday. Appreciate Holdings received a notice from Nasdaq regarding... 
Via Benzinga
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Why Microsoft Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million... 
Via Benzinga
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Participation in Upcoming September Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics – Could This Company's Technology Make Debilitating Neural Diseases Like Dementia A Thing Of The Past?
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic... 
Via Benzinga
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Rises Sharply; Unifirst Earnings Miss Expectations
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.32% to 33,818.48 while the NASDAQ rose 0.23% to 13,586.93. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market. 
Via Benzinga
Nasdaq Moves Higher; US Crude Stocks Drop More than Projected
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 80 points on Wednesday. The Dow traded down 0.42% to 33,784.59 while the NASDAQ rose 0.63% to 13,640.83. The S&P... 
Via Benzinga
Why Cognition Therapeutics Stock Is Plunging On Alzheimer's Disease Related News Today
Cognition Therapeutics Inc (NASDAQ: CGTX) announced the topline results from its Phase 2 double-blind, single-crossover SEQUEL study of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease. 
Via Benzinga
Dow Drops 100 Points; General Mills Posts Downbeat Sales
U.S. stocks traded lower this morning, with the Dow Jones dropping around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.30% to 33,823.27 while the NASDAQ fell... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
Call and webcast will take place at 8:00am ET 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.